Saturday 17 October 2026
Export INAB’s income statement to Excel — free account
IN8bio, Inc.
INAB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 79.8% and free cash flow fell 1.30%, each against the same quarter a year earlier.
1.11
0.08
−6.72%
Follow INAB
IN8bio, Inc. (INAB) P/E ratio
IN8bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| PTN Palatin Technologies, Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| INAB IN8bio, Inc. | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| ASBP Aspire-Lakewood Holdings, Inc. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)